Pentadeca Arginate research monograph — BPC-157 in an arginate salt, and the limits of its evidence base

Pentadeca Arginate (PDA) is a synthetic pentadecapeptide — a salt-form variant of BPC-157. It has the identical 15-amino-acid sequence (GEPPPGKPADDAGLV) but is formulated with an arginate (arginine) counterion instead of the usual acetate. It is also sold as "Pentadeca Arginate Complex," "PDA," or "BPC-157 Arginate."

Class

Synthetic pentadecapeptide; an arginate salt form of BPC-157. Single compound.

Mechanism

PDA shares the exact 15-amino-acid sequence of BPC-157 (GEPPPGKPADDAGLV); the only difference is the salt/counterion (arginate vs acetate). Its proposed mechanism is therefore BPC-157's: promotion of angiogenesis and tissue repair, modulation of growth-factor pathways (notably upregulation of VEGFR2 and the nitric-oxide system), and cytoprotective effects on gut, tendon, muscle and nerve in animal models. The arginate salt is claimed to improve stability; the biological action is presumed identical because the active sequence is unchanged.

Research summary

The crucial honest point: no peer-reviewed study has investigated Pentadeca Arginate as a distinct molecule. Every claim about PDA is inferred from the BPC-157 literature, which is itself almost entirely preclinical (rodent models of tendon, ligament, muscle, gut and nerve healing) with no large, controlled human trials. The "PDA-specific" evidence that vendors imply does not exist. Database searches for "PDA"/"arginate" return unrelated work — patent ductus arteriosus, pancreatic adenocarcinoma, heme arginate — none about this peptide.

Studied protocols

None studied for PDA specifically. Community and clinic use mirrors BPC-157 practice (subcutaneous injection, commonly around 250–500 mcg once or twice daily in informal use; oral/capsule forms are marketed on the stability premise). These reflect community practice, not research-validated dosing, and carry the same caveats as BPC-157.

Stacking research

No published stacking research for PDA. In community practice it is paired with TB-500 / BPC-style soft-tissue blends (e.g. "Wolverine"-type stacks), but no controlled combination studies exist. The BPC-157 monograph is the most relevant cross-reference.

Clinical / safety context

Not approved for human use; sold research-use-only. No regulated safety data exist for the arginate form. BPC-157 shows a generally benign profile in animal studies but lacks human safety trials, and the FDA has placed BPC-157 in the category of substances that do not qualify for compounding. The widely repeated "1,000x more stable at pH 3.0" claim is compounding-pharmacy marketing and has not been published in any peer-reviewed journal.

Evidence quality — Limited / by-extension only

Despite a large indexed-document count, there is zero direct research on Pentadeca Arginate as a molecule. All plausible activity is inferred from BPC-157's mostly-preclinical record. Treat PDA as "BPC-157 in a different salt"; weight any claim to BPC-157's evidence — itself preclinical-dominant with no human trials. The enhanced-stability selling point is unverified.

Notes

"Pentadeca" = 15 (a pentadecapeptide); "Arginate" = arginine salt. Same active sequence as BPC-157, marketed as more stable (especially for oral dosing). Buyers are purchasing BPC-157 in an arginate salt, not a novel compound with its own evidence base. For mechanism and the (preclinical) research, the BPC-157 monograph is the canonical reference.